NCT04639024 - ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

November 3, 2022

Study Completion Date

November 3, 2022

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Myeloproliferative Neoplasm (MDS/MPN)

Interventions

DRUG

ADCT-301

Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.

Trial Locations (1)

27705

Duke University Health System, Durham